OR WAIT null SECS
The Chinese government's investments in the biopharmaceutical sector may help it become one of the leading industries in China by 2020.
China's biopharmaceutical industry is entering what some have termed a "Golden Age." The outlook, although generally positive, presents a number of hurdles that may dampen short-term optimism for investors and businesses. But the prognosis, given the current demographic, political, economic, and healthcare situation in China, is positive.
Eliza Yibing Zhou
A unique aspect of China's economic planning is its Five-Year Plan, the national economic development guidance that outlines the country's overall development in five-year periods. The Chinese central government established the plan in 1953 as an approach for allocating the national resources necessary for construction, development, and economic expansion. The 11th Five-Year Plan is for 2006–2010.
This latest plan includes continued investments by the central government in the biopharmaceutical sector to help it become one of the leading industries in China by 2020. The specific objectives for healthcare appear in the "Guidelines for the Healthcare Industry" that were issued last September, based on the national 11th Five-Year Plan.* The principal objectives of the Chinese healthcare industry include:
To evaluate the near-term development of China's biopharmaceutical industry, however, it is useful to do more than examine the governement's planning goals, BioPlan Associates has developed more specific projections about China's biopharmaceutical industry, based on data and information from the recent study, Advances in Biopharmaceutical Technology in China, copublished by BioPlan Associates and the Society for Industrial Microbiology. The study indicates that China's biopharmaceutical sales totaled RMB 30.31 billion ($3.9 billion) in 2005 and its 2006 sales are estimated to exceed RMB 36 billion ($4.6 billion). Despite the impact of additional drug price cuts mandated by the government, we predict the Chinese biopharmaceutical industry will continue to see moderate growth through the end of the decade. Over the next five years, we project a rate of 22%, to 80 billion RMB (~$10.3 billion) through 2010. The primary drivers in the industry will be vaccine and protein therapeutics.
"China's biopharmaceutical industry is now embracing strong development opportunities," said Lifeng Wang, CEO of China National Biotech Group (CNBG) at the First International China Biopharmaceutical Symposium (ICBPS) that was held in Beijing in December 2006. "Chinese biopharma enterprises are looking forward to more collaboration with the world's leading biopharma institutions and companies. We expect to achieve a win-win situation with our global partners. The Chinese biopharmaceutical industry is ready to make significant contributions to global disease prevention and healthcare," she added.
CNBG is the largest vaccine manufacturer in China and controls six biological product research institutes and two manufacturing companies. China's vaccine sector is a bright spot in the biopharmaceutical industry. Because of its population, the country is currently the world's fourth largest vaccine market, following the US, Germany, and Japan. As China's population approaches 1.36 billion by 2010 and 1.45 billion by 2020, the country will most likely become the world's largest vaccine market in the future. This change is driven by market demand, a thriving economy, and an improving healthcare system.
China's biopharmaceutical industry has witnessed 20% to 30% revenue growth annually since 2001. Today, China is home to more than 400 biopharmaceutical manufacturers, including 114 manufacturers of genetically engineered drugs and 28 vaccine manufacturers. Over 30 domestically produced protein therapeutic drugs and 41 vaccines have been commercialized in China. The country also exports vaccines, recombinant insulin, and other biochemical raw materials.
Certainly, in the global landscape, the Chinese biopharmaceutical industry remains small, accounting for less than 7% of the world's total biopharmaceutical market. Also, 95% of the Chinese domestic biopharmaceutical market is made up of biogenerics (copies of biotherapeutics developed outside China). The overall innovative capability of the industry today is quite limited. Most manufacturers are very conservative and their investments in product R&D are small, because of lack of capital and venture capital (VC) support. Government funds and grants are not sufficient to subsidize major research projects at biopharmaceutical companies. As a result, Chinese organizations have sought subsidies and investments from banks and other capital markets, both domestic and international. Today, public and university research institutes receiving government funds play a key role in the R&D of biopharmaceuticals.
In addition to producing a variety of biogenerics to supply its domestic market, China has succeeded in developing and commercializing several innovative biotech drugs and vaccines. Some research-oriented Chinese biopharmaceutical companies such as Shanghai Sunway Biotech, Yantai Medgenn, and Beijing Biotech Pharma have developed a handful of novel protein therapeutic drugs. These companies have won grants from the National 863 Program, a Chinese government-sponsored technology support program that has funded the R&D of more than 300 new biotech drugs across the country. Beijing Biotech Pharma has attracted foreign investment from a variety of sources, including Cuba, but it has yet to see substantial market penetration for its key product—hR3 MAb.
A number of trends are emerging in China, including regulatory, enterprise, and IP. Some of these are outlined below.
In many countries, government support is one of the most important forces fueling biotech development. The Chinese government emphasizes the biopharmaceutical industry in the 11th Five-Year Plan period. China's National Medium-and Long-Term Science and Technology Development Plan Outline (2006–2020) indicates that in the next 15 years, China will deploy a series of cutting-edge technologies in the biotechnology sector. These include target discoverY; animal and plant species and drug molecular design; gene operation and protein engineering; human tissue engineering based on stem cells; and a new generation of industrial biotechnology. The government also will increase investment in the biopharmaceutical sectors.
China is making strides in protecting IP rights in conformity with World Trade Organization requirements. This trend will continue in the future, and these efforts are leading to increasing confidence in China's IP protection system. For example, this improved IP protection was a key reason Novartis chose to set up its eighth global R&D center in China in November 2006. Several other multinational companies also have established R&D centers in China.
China's State Food and Drug Administration (SFDA) is modifying policies to encourage innovation and restrict imitation. It is also issuing policies to encourage biopharmaceutical outsourcing. Moreover, the country is on the way to establishing an effective VC system to attract foreign venture capital in the biotech sector.
The government has conducted 19 waves of drug price cuts and is planning more in the coming years. This may affect the country's biopharmaceutical revenue growth but will benefit Chinese consumers. The overall increase in volume may offset the reduction on per-unit revenue.
The biopharmaceutical industry is driven by novel technologies to a great extent. A study conducted by the Tongji Investment Institute, based on a survey of over 100 senior Chinese experts, has indicated trends in China's biopharmaceutical technology development (see the box, "Technology Trends in China).1 These experts were chosen from organizations such as CNBG, the National Human Genomics Institute, the China Disease Prevention and Control Center, the Chinese Academy of Sciences, Beijing Four-rings Biopharma, and Triprime Gene.
Technology Trends in China
Chinese biopharmaceutical companies are forming strategic alliances to enhance their overall strength. For example, China's biopharma giant, CNBG, was formed by merging six major biological product institutes in Beijing, Shanghai, Changchun, Wuhan, Lanzhou, and Chengdu with two biopharma manufacturers (Beijing Tiantan and Chengdu Rongsheng). The resulting organization employs 10,000 people across China. On the other hand, small-to-medium sized biotech companies with one or two new products are collaborating with big companies with strong financial, facilities, and sales network support.
The Chinese central and local governments have built more than 100 biopharmaceutical parks across China. Shanghai Zhangjiang High-tech Park is a successful example. More than 100 domestic and international biopharmaceutical companies and central research organizations (CROs) are located there, including Roche, Novartis Biomedical Research Co., Kirin Kunpeng Biopharma, Wuxi Pharma Tech., Shanghai Lead Discovery. Despite these successes, however, many Chinese high-tech parks continue to have a high vacancy rate and are well below capacity.
Chinese biopharmaceutical companies are becoming aware of the need for R&D investment and are actively seeking sources of funding for product R&D. Several biopharmaceutical organizations are attempting to establish effective technology platforms to meet the needs a range of needs in upstream R&D, pilot experiments, and clinical studies, and downstream production. For example, Shenyang Sunshine Pharma, which insisted on investing 10% of its sales income on new product R&D, has been rewarded by the successful development of rh TPO, EPO, and other profitable products.
With a growing number of overseas Chinese returning to China and taking important positions in Chinese biopharmaceutical companies and institutes, international collaborations are playing an increasingly important role in the community. This has become an important trend in the industry.
Most of the world's best-selling biopharmaceuticals use mammalian cell culture technology platforms. In China, however, many manufacturers still rely on less expensive E. coli technology platforms in production. Relatively few products are produced through mammalian cell expression. It is likely that Chinese biopharmaceutical companies that manage high-efficiency mammalian cell expression technology and scale-up cultivation technologies will be rewarded in the domestic market.2
Over the next 15 years, China is projected to become one of the world's major biopharmaceutical players, along with the US, Europe, and Japan. Now that China has opened its window to the world, its biopharmaceutical industry will see more opportunities. To succeed, Chinese biopharmaceutical companies must foster innovation, collaborate with the world's leading biopharmaceutical enterprises, and strengthen their technologies by integrating domestic and foreign resources. To the extent that Chinese biopharmaceutical organizations follow this approach, they will become a major force in the world biopharmaceutical markets.
Eliza Yibing Zhou is project director for research programs on China and India at BioPlan Associates Inc., 301.921.9074, email@example.com
1. Yi H, Chen D. Prediction analysis of the technological development trend for biopharmaceutical industry in China. Advances in Biopharm Technol in China. 2006;9:1153–59.
2. Liu W, Chao C. Current status and expectation of the biopharmaceutical industry in China. China Biotechnol. 2006;26(6):103–7.